title: Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders.
abstract: We monitored serum levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) before and during intravenously applied immunoglobulin (IVIG) therapy in 33 patients with chronic immune-mediated neuropathies and myopathies and 15 controls. Baseline MMP-2 and TIMP-2 serum levels were lower and MMP-9 and TIMP-1 serum levels higher in all patients compared to age-matched controls. Eight days after IVIG treatment, MMP-2, TIMP-2, and TIMP-1 serum levels increased, while MMP-9 serum levels decreased, indicating tissue repair. After 60 days, MMP-9 levels increased, MMP-2 approached normal levels, while TIMP-1 and TIMP-2 serum levels were below day 8 levels, indicating relapsing tissue damage. Comparing the MMP/TIMP results with the clinical courses, IVIG treatment tended to change MMP/TIMP levels in a way that paralleled clinical improvement and relapse. In sum, during a distinct time period, IVIG therapy seems to be able to modulate MMP-mediated tissue repair.
authors.affiliation: Friedrich Baur Institute, Department of Neurology, Ludwig Maximilian University Munich, Munich, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Hurnaus
authors.forename: W
authors.initials: W
authors.lastname: Mueller-Felber
authors.forename: D
authors.initials: D
authors.lastname: Pongratz
authors.forename: B G H
authors.initials: BG
authors.lastname: Schoser
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D008875:Middle Aged; D018979:Myositis, Inclusion Body / Q000097:blood / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D009468:Neuromuscular Diseases / Q000097:blood / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood*
chemical_list: D016756:Immunoglobulins, Intravenous; D019716:Tissue Inhibitor of Metalloproteinase-2; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9